10-K: Septerna's 10-K Filing Reveals Setback in Hypoparathyroidism Drug Development, Shifts Focus to Next-Generation Candidate

Septerna's 10-K filing details a strategic shift in their hypoparathyroidism program following adverse events in a Phase 1 trial, alongside updates on their broader GPCR-targeted drug development pipeline.

Summary

• Septerna's 10-K filing provides an overview of the company's business, financial performance, and future outlook.
• The company is focused on developing oral small molecule drugs targeting GPCRs, initially in endocrinology, immunology and inflammation, and metabolic diseases.
• A Phase 1 clinical trial of SEP-786, a PTH1R agonist for hypoparathyroidism, was discontinued due to severe adverse events.
• Septerna plans to advance a next-generation oral small molecule PTH1R agonist into clinical development later in the year.
• SEP-631, an MRGPRX2 NAM for CSU, is expected to enter Phase 1 clinical trials in 2025.
• The company is also developing a TSHR NAM for Graves' disease and TED, with lead compounds advancing towards IND-enabling studies.
• Incretin programs are underway, focusing on oral small molecule singleand multi-incretin receptor agonists for metabolic disorders.
• Septerna had $420.8 million in cash, cash equivalents, and marketable securities as of December 31, 2024, expected to fund operations into early 2028.
• The company anticipates increased operating expenses in the coming years as it progresses its pipeline and operates as a public entity.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in the pipeline and sufficient cash runway, the setback in the lead program and ongoing losses temper the outlook.

Positives

• Septerna is advancing multiple lead compounds towards selection of a next-generation oral small molecule PTH1R development candidate to complete IND-enabling studies and accelerate toward clinical development later this year.
• SEP-631 has been demonstrated to potently block the activation of intracellular signaling in HEK293 cells with overexpressed human MRGPRX2 stimulated by cortistatin-14 (IC50 = 1.6 nM).
• SP-1351 was able to inhibit the activity of 10 out of 10 polyclonal sera samples, each from a different Graves disease patient.
• Oral small molecule mono-GIPR agonists with favorable PK properties have demonstrated the ability to achieve glucose control in a mouse model of glucose sensitivity and demonstrated weight loss in a DIO mouse model as a single agent and additive weight loss when dosed in combination with semaglutide.

Negatives

• The Phase 1 clinical trial of SEP-786 was discontinued due to two severe (Grade 3) events of elevated unconjugated bilirubin.
• The company has incurred significant operating losses since its inception and expects to continue to incur significant losses for the foreseeable future.
• The company has a limited operating history and has not successfully completed any clinical studies.
• The company's proprietary Native Complex Platform TM is based on novel technologies that are unproven and may not result in approvable or marketable products.

Risks

• The company will require substantial additional funding in order to finance its operations.
• Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes.
• Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval.
• The company faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.
• The company relies on third-party manufacturers, clinical research organizations (CROs), contract manufacturing organizations (CMOs), and suppliers to supply, develop and test components of our product candidates.

Future Outlook

Septerna plans to advance a next-generation oral small molecule PTH1R agonist into clinical development later in the year, advance SEP-631 into Phase 1 clinical trials in 2025, continue to advance the other programs in its pipeline, and fund working capital and other general corporate purposes.

Industry Context

The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary and novel products and product candidates. Septerna faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.

Comparison to Industry Standards

• Several other companies also focus on GPCRs and have platform technologies that are distinct from our Native Complex Platform TM , including Nxera Pharma (formerly Sosei Heptares), Structure Therapeutics, Tectonic Therapeutics, and Confo Therapeutics.
• There are also several currently approved injectable products targeting incretin receptors for the treatment of obesity or type 2 diabetes (T2D). These include, but are not limited to, products such as Ozempic and Wegovy (semaglutide, each marketed by Novo Nordisk) for T2D and obesity, respectively, Trulicity (dulaglutide, marketed by Eli Lilly and Company) for T2D, and Mounjaro and Zepbound (tirzepatide, each marketed by Eli Lilly and Company) for T2D and obesity, respectively.

Management Changes

Related Party Transactions

• Issued Series B Convertible Preferred Stock to Third Rock Ventures and RA Capital Management.
• Service agreement with Third Rock Ventures, LLC.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Potential impact on job security and compensation due to financial performance.
• Patients: Potential for new treatment options, but also risk of delays or failures in drug development.

Next Steps

• Advance a next-generation oral small molecule PTH1R agonist from the PTH1R program into clinical development.
• Advance SEP-631 into Phase 1 clinical trials.
• Continue to advance the other programs in the pipeline.
• Continue to optimize multiple early-stage oral small molecule TSHR NAMs, with the goal of advancing lead compounds towards selection of a development candidate for IND-enabling studies.
• Continue to optimize multiple early-stage oral small molecule incretin receptor agonists and plan to continue evaluating them in a variety of metabolic models with a goal of advancing lead compounds towards selection of one or more development candidates for IND-enabling studies.

Key Dates

Keywords

GPCR, PTH1R, MRGPRX2, TSHR, Incretin, Hypoparathyroidism, Graves Disease, Thyroid Eye Disease, Metabolic Disorders, Biotechnology, Pharmaceutical, Clinical Trials, Drug Development, Native Complex Platform